![Jan Mikkelsen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jan Mikkelsen
Grundare på
ASCENDIS PHARMA A/S
Profil
Jan Møller Mikkelsen was the founder of Profound Pharma AS, founded in 1999, where the title held was Co-Chief Executive Officer.
Mr. Mikkelsen is the founder of Ascendis Pharma A, founded in 2006, holding the title of President, CEO & Executive Director.
Current jobs include Chief Executive Officer & Director at Ascendis Pharma Endocrinology Division A since 2012; Chief Executive Officer at Ascendis Pharma Bone Diseases A; Chief Executive Officer at Ascendis Pharma Growth Disorders A; Chairman at Hummingbird Bioscience Holdings Pte Ltd. since 2021; Director at VISEN Pharmaceuticals (Shanghai) Co., Ltd.; and Senior Advisor at Frazier Management LLC since 2022.
Former jobs include President & Chief Executive Officer at Veloxis Pharmaceuticals A from 2002 to 2006; Non-Executive Director at VISEN Pharmaceuticals from 2018 to 2025; President-Pharmaceutical Division at Maxygen, Inc. from 2000 to 2002; and Vice President-Protein Discovery at Novo Nordisk A in 1999.
Education includes undergraduate studies at the University of Southern Denmark.
Aktiva positioner av Jan Mikkelsen
| Företag | Position | Start |
|---|---|---|
| ASCENDIS PHARMA A/S | Grundare | 2006-09-21 |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Manufactures endocrine pharmaceutical products | Verkställande Direktör | 2012-06-29 |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. BiotechnologyHealth Technology Develops endocrine disease therapies | Direktör/Styrelseledamot | - |
Ascendis Pharma Bone Diseases A/S | Verkställande Direktör | - |
Ascendis Pharma Growth Disorders AS | Verkställande Direktör | - |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm targets companies operating in the fields of medical products & distribution, pharmaceuticals and healthcare service sectors. It provides financing for buyout and growth stage capital requirements. | Konsult / Rådgivare | 2022-01-01 |
Hummingbird Bioscience Holdings Pte Ltd.
 Hummingbird Bioscience Holdings Pte Ltd. MiscellaneousMiscellaneous Functions as an investment holding company | Ordförande | 2021-01-01 |
Tidigare kända positioner av Jan Mikkelsen
| Företag | Position | Slut |
|---|---|---|
| VISEN PHARMACEUTICALS | Direktör/Styrelseledamot | 2025-06-27 |
| VELOXIS PHARMACEUTICALS A/S | Verkställande Direktör | 2006-01-01 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░░░░ | - |
| ░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Jan Mikkelsens utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
67
Första gradens relationer
13
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 13 |
|---|---|
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm targets companies operating in the fields of medical products & distribution, pharmaceuticals and healthcare service sectors. It provides financing for buyout and growth stage capital requirements. | Finance |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Commercial Services |
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
Profound Pharma AS
 Profound Pharma AS Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
University of Southern Denmark
 University of Southern Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma A/S
 Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapies for metabolic, cardiovascular and ophthalmology | Health Technology |
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Manufactures endocrine pharmaceutical products | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. BiotechnologyHealth Technology Develops endocrine disease therapies | Health Technology |
Ascendis Pharma Bone Diseases A/S | |
Hummingbird Bioscience Holdings Pte Ltd.
Hummingbird Bioscience Holdings Pte Ltd. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Ascendis Pharma Growth Disorders AS | |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes paradigm-shifting endocrine therapies | Health Technology |
